How Drug Developers can Navigate the Inflation Reduction Act of 2022
Learn how the IRA will impact how new drugs are marketed and why negotiating pricing…
Certara2023 年 1 月 27 日
Exceling at Accelerating in Rare Disease Drug Development
By: Rajesh Krishna, PhD, FAAPS and Steve Sibley According to the National Institutes of Health,…
Certara2023 年 1 月 26 日
Exposure-Response Analyses of Tremelimumab Monotherapy or in Combination with Durvalumab in Patients with Unresectable Hepatocellular Carcinoma
An novel single dose regimen of tremelimumab combined with durvalumab could be a way to…
Certara2023 年 1 月 26 日
Tips & Tricks for Streamlining Non-compartmental Pharmacokinetic Analysis
These Phoenix tips and tricks will help you exclude Lambda Z, name partial areas, and…
Certara2023 年 1 月 20 日
D360 as your organization’s extendable and central data engine
D360 is an industry-leading scientific data informatics platform providing a flexible, scalable, and customizable enterprise…
Certara2023 年 1 月 20 日
Physiologically-Based Pharmacokinetic Modeling & Simulation to Support Asciminib NDA Submission & Inform Drug Product Label
Physiologically based pharmacokinetic (PBPK) modeling and simulation has become an established approach to assess drug-drug…
Certara2023 年 1 月 13 日
Certara Awarded NIH Contract for Toxicology Consulting Support
Certara toxicology experts to support NIH’s BPN and HEAL drug development programs for nervous system…
Certara2023 年 1 月 10 日
Ghent University wins the 2021/22 Certara-Simcyp Grant and Partnership Scheme
PRINCETON, N.J., 2023 年 1 月 9 日 — Certara, Inc. （纳斯达克股票代码：CERT), a global leader in biosimulation,…
Certara2023 年 1 月 9 日
